Hepatitis C Drug BMS-790052 and BMS-650032 to be Presented at The International Liver Congress 2011

Watch for updates
Note the link provided on this blogs sidebar;
The International Liver Congress™ 2011 by EASL (46th annual meeting)

BRISTOL-MYERS SQUIBBDL-10 : New Data on Multiple Bristol-Myers Squibb Investigational Hepatitis C Compounds to be Presented at The International Liver Congress 2011
03/07/2011 01:55 pm

New Phase II data on multiple Bristol-Myers Squibb Company (NYSE: BMY) investigational hepatitis C compounds will be presented at The International Liver Congress (ILC), the 46th annual meeting of the European Association for the Study of the Liver (EASL) in Berlin, Germany, from March 30 to April 2. The data presentations, including three late-breaker presentations, demonstrate the rigorous execution of the company's strategy to develop potential improvements in the care of patients living with Hepatitis C infection by using multiple approaches to target the virus.

Bristol-Myers Squibb will present three late-breaker presentations, including a poster presentation of the first public disclosure of 12-week data on sustained virologic response (SVR) with the NS5A inhibitor BMS-790052 in combination with PEG-Interferon alpha-2a and ribavirin (IFN?/RBV) in treatment-naïve HCV patients. Additionally, SVR 12-week data on quadruple therapy with BMS-790052, the NS3 inhibitor BMS-650032 and IFN?/RBV in null responders will be presented in the late-breaker oral presentation session on Saturday, April 2. Complete early virology response (cEVR) data from the Phase IIb EMERGE study of PEG-Interferon lambda and ribavirin versus IFN?/RBV in treatment-naïve patients will also be presented in a late-breaker oral presentation.

Bristol-Myers Squibb is focused on advancing the science to address significant unmet medical needs for patients with liver disease,? said Brian Daniels, MD, senior vice president, Global Development and Medical Affairs, Research and Development, Bristol-Myers Squibb. ?The data at the International Liver Congress reflect the breadth of our hepatitis C pipeline and the multiple approaches we are taking to bring forward potential new options for a disease that today impacts approximately 170 million people worldwide.

BMS-790052 and BMS-650032 were discovered by Bristol-Myers Squibb Research and Development. PEG-Interferon lambda was discovered by ZymoGenetics, Inc., a wholly-owned subsidiary of Bristol-Myers Squibb.
The Bristol-Myers Squibb data presentations at ILC are as follows:
Date/Time

Presentation Title

Lead Author
March 31

First report of SVR12 for a NS5A Replication complex inhibitor, BMS-790052 in combination with PEG-IFN?-2A and RBV: Phase 2a trial in treatment-naïve HCV-Genotype 1 subjects (Poster Board # 1373)

S. Pol
Hôpital Cochin
Paris, France
April 1

In Vitro DAA combination studies to address HCV clinical findings (Poster Board # 803)

J.A. Lemm
Bristol-Myers Squibb
April 1

BMS-766, A Novel HCV NS5a inhibitor with enhanced resistance coverage (Poster Board # 787)

M. Gao
Bristol-Myers Squibb
April 1,
4:45 –5:00 p.m.

Characterization of Virologic Escape in
HCV Genotype 1 Null responders
receiving a combination of the NS3 protease inhibitor BMS-650032 and NS5A inhibitor BMS-790052 (Oral Session)

F. McPhee
Bristol-Myers Squibb
April 2

BMS-650032, an NS3 inhibitor, in combination with Peginterferon Alfa-2a and Ribavirin in treatment-naïve subjects with genotype-1 chronic hepatitis C infection (Poster Board # 1195)

J. Bronowicki
Hôpital Adultes De Brabois
Vandoeuvre Les Nancy, France
April 2

No early virologic breakthrough observed with the HCV NS3 protease inhibitor BMS-650032 in multiple dose monotherapy studies and Phase 2a combination studies with PEG-INF alpha/RBV (Poster Board # 1223)

F. McPhee
Bristol-Myers Squibb
April 2

The burden of hepatitis C in Europe: a propensity analysis of patient outcomes (Poster Board # 1192)

M. daCosta DiBonaventura
Kantar Health
New York, New York
April 2

Estimating the incidence and prevalence of hepatitis C infection in England using back projection methods (Poster Board # 1166)

P. McEwan
Cardiff Research Consortium
Cardiff, UK
Swansea University
Swansea, UK
April 2

Cost benefit analysis of response guided therapy: dynamic disease Markov modeling for patients with chronic hepatitis (HCV) by fibrosis stages (Poster Board # 1167)

P. McEwan
Cardiff Research Consortium
Cardiff, UK
Swansea University
Swansea, UK
April 2,
3:30 – 5:30 p.m.

Pegylated Interferon-Lambda (PEGIFN-?) shows superior viral response with improved safety and tolerability versus PEGIFN?-2A in HCV patients (G1/2/3/4): EMERGE Phase IIb through week 12 (Late-Breakers Oral Session)

S. Zeuzem
Klinikum der Johann-Wolfgang Goethe-Universität, Frankfurt/Main, Germany
April 2,
3:30 – 5:30 p.m.

Quadruple therapy with BMS-790052, BMS-650032 and PEG-IFN/RBV for 24 weeks results in 100% SVR12 in HCV Genotype 1 null responders (Late-Breakers Oral Session)

A. Lok
University of Michigan
Ann Arbor, Michigan
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.bms.com&esheet=6637249&lan=en-US&anchor=http%3A%2F%2Fwww.bms.com&index=4&md5=e27c5903d4cf1e391f5e629af94a8f3d or follow us on Twitter at http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Ftwitter.com%2Fbmsnews&esheet=6637249&lan=en-US&anchor=http%3A%2F%2Ftwitter.com%2Fbmsnews&index=5&md5=7b21c7aa2f44315a9d3f54513218c782.